SCOPE Ph 2 data shows strongly improved outcomes in Late-Stage Melanoma with iSCIB1+
Dr Nermeen Varawalla, Chief Medical Officer of Scancell, said: “iSCIB1+ has shown meaningful benefits in terms of responses, disease control, progression-free survival and immune responses, which offer a potentially huge improvement for patients. Furthermore, its strong safety profile suggests that iSCIB1+ could be used in addition to SoC without adding toxicities. These data demonstrate the potential of iSCIB1+ in patients with metastatic melanoma as well as highlight the significant potential in earlier stage resectable disease when administered in the neoadjuvant / adjuvant setting. The results also provide the option of a biomarker to predict responders which could be a significant advantage in selecting participants in a future registrational study.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines